Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Valiant Laboratories IPO
Valiant Laboratories Limited
₹75 /1 sharesMinimum Investment
Valiant Laboratories IPO Details
| Bidding Dates | Min. Investment | Lot Size | Price Range |
|---|---|---|---|
| 28 Jul ‘25 - 8 Aug ‘25 | ₹7,875 | 1 | ₹75 - ₹75 |
| Issue Size | IPO Doc |
|---|---|
| 152.46Cr | RHP PDF |
Subscription rate
| Qualified Institutional Buyers | 20.83x |
| Non-Institutional Investor | 73.63x |
| Retail Individual Investor | 16.04x |
| Employees | 0.00x |
| Total | 29.75x |
About Valiant Laboratories
Founded in
2021
Managing director
Mr. Santosh Shantilal Vora
Parent organisation
Valiant Laboratories Limited
Strengths & Financials of Valiant Laboratories
Strengths
Risks
Between 2017 and 2023, the company saw a consistent increase in revenue from operations, with a compounded annual growth rate (CAGR) of 23.90%. Similarly, the restated profit after tax also exhibited growth, recording a CAGR of 26.81% during the same period.
The company’s quality control team monitors the manufacturing process at all stages, from the initial testing stage for incoming raw material to the final product before packing.
In terms of sourcing raw materials, Valiant Laboratories imports Para Amino Phenol, a crucial component for Paracetamol manufacturing, from suppliers in China and Cambodia. The company has reduced its dependence on external suppliers. Instead, it now procures this essential raw material through its promoter group company, Valiant Organics Limited.
Valiant Laboratories strategically positions its Manufacturing Facility, located approximately 150 kilometers away from JNPT (Nhava Sheva) Port in Navi Mumbai, Maharashtra. It is situated about 110 kilometers from the company's registered office in Mulund West, Mumbai, Maharashtra. It enables the company to have swift access to port facilities, facilitating the timely import of raw materials and efficient export of its products.
Any fluctuations or changes in the paracetamol API industry or shifts in product demand could have a detrimental effect on Valiant Laboratories' revenue and overall financial performance.
Valiant Laboratories operates solely from a single manufacturing facility situated in Palghar, Maharashtra. Any localized social unrest, natural disasters, service breakdowns, or disruptions in production at this facility could significantly harm the company's business and financial condition.
The company relies on a limited number of suppliers for its raw materials, primarily concentrated in the western region of India.
The company's revenue is heavily dependent on a small number of customers. The absence of long-term arrangements with these customers poses a risk, as any failure to continue existing arrangements could negatively affect the business and operational results.
Exposure to counterparty credit risk means that delays or non-receipt of payments could have an adverse impact on the company's operational results.
The company faces potential adverse effects on its results of operations due to fluctuations in exchange rates, particularly as it engages in exports and incurs expenses in foreign currencies.
The company, its promoters, and its directors are involved in certain legal proceedings. Unfavorable outcomes in these cases could harm the company's reputation, business, financial condition, and cash flows.
Valiant Laboratories Financials
*All values are in Rs. Cr
No Graph Data To Display
Application Details of Valiant Laboratories IPO
| Apply as | Price band | Apply Range |
|---|---|---|
| Regular | ₹133 - 140 | Upto ₹2 Lakh |
| High Networth Individual | ₹133 - 140 | ₹2 - 5 Lakh |
For Valiant Laboratories IPO, eligible investors can apply as Regular.